Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

CRD and CHE Technology Assessment Group; Mark Rodgers; Marta O Soares; D. Epstein; Huiqin Yang; Alison Jane Eastwood

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

CRD and CHE Technology Assessment Group, Mark Rodgers, Marta O Soares, D. Epstein, Huiqin Yang, Alison Jane Eastwood

Research output: Book/Report › Other report

Original language	English
Publisher	Centre for Reviews and Dissemination/ Centre for Health Economics
Publication status	Published - 2010

Access to Document

http://www.hta.ac.uk/erg/reports/2241.pdf

Cite this

@book{f8865ee178084bbb91982230cc70df11,

title = "Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.",

author = "{CRD and CHE Technology Assessment Group} and Mark Rodgers and {O Soares}, Marta and D. Epstein and Huiqin Yang and Eastwood, {Alison Jane}",

year = "2010",

language = "English",

publisher = "Centre for Reviews and Dissemination/ Centre for Health Economics",

}

TY - BOOK

T1 - Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

AU - CRD and CHE Technology Assessment Group

AU - Rodgers, Mark

AU - O Soares, Marta

AU - Epstein, D.

AU - Yang, Huiqin

AU - Eastwood, Alison Jane

PY - 2010

Y1 - 2010

M3 - Other report

BT - Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

PB - Centre for Reviews and Dissemination/ Centre for Health Economics

ER -